Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trimethoprim

FDA-approved product (tablet, oral), marketed as Proloprim, Trimethoprim, Trimpex and 2 more.

Registered studies
50+
Lab records
56
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Trimethoprim
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Otitis media
  • Pneumocystosis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Trimethoprim and derivatives
FDA pharmacologic class
Dihydrofolate Reductase Inhibitor Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01EA01; FDA class Dihydrofolate Reductase Inhibitor Antibacterial

Repurposing investigation

Trimethoprim is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA79.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae76.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis9.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 7 of 8 lab records
  • E. coli: measured active in 32 of 33 lab records
  • K. pneumoniae: measured active in 7 of 12 lab records
  • M. tuberculosis: measured active in 0 of 3 lab records
Open Trimethoprim in ChEMBL Registered studies below
Show the 56 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trimethoprim with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial

    NCT00490477 · start 2006-05

    Registered record
    Registry ID
    NCT00490477
    Conditions
    Gram-Negative Bacterial Infections; Sepsis
    Interventions
    Polymyxin -B fiber hemoperfusion system
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Negative Bacterial Infections; Sepsis
    InterventionPolymyxin -B fiber hemoperfusion system
    PhasePhase 3
    Registry statusCompleted

  • Use of Amnion on Partial Thickness Burns

    NCT00674999 · start 2005-06

    Registered record
    Registry ID
    NCT00674999
    Conditions
    Burn
    Interventions
    Amnion; Amnion; Polysporin/Bacitracin/Mycostatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2005-06
    Completion
    2008-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurn
    InterventionAmnion; Amnion; Polysporin/Bacitracin/Mycostatin
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

    NCT00000635

    Registered record
    Registry ID
    NCT00000635
    Conditions
    Herpes Simplex; HIV Infections
    Interventions
    Trifluridine; Bacitracin zinc/Polymyxin B sulfate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1992-04
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Simplex; HIV Infections
    InterventionTrifluridine; Bacitracin zinc/Polymyxin B sulfate
    PhaseNot applicable
    Registry statusCompleted

  • Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock

    NCT02825329

    Registered record
    Registry ID
    NCT02825329
    Conditions
    Septic Shock; Endotoxemia
    Interventions
    TORAYMYXIN PMX-20R
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Temporarily not available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock; Endotoxemia
    InterventionTORAYMYXIN PMX-20R
    PhaseNot recorded
    Registry statusTemporarily not available

  • Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

    NCT04352985

    Registered record
    Registry ID
    NCT04352985
    Conditions
    Septic Shock; Endotoxemia; COVID; Corona Virus Infection; Sepsis, Severe
    Interventions
    Toraymyxin PMX-20R (PMX Cartridge)
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock; Endotoxemia; COVID; Corona Virus Infection +1 more
    InterventionToraymyxin PMX-20R (PMX Cartridge)
    PhaseNot recorded
    Registry statusNo longer available